Zucara Therapeutics Successfully Completes Single and Multiple Ascending Dose Phase 1 Trial of ZT-01

Ontario Industry Updates
Written By Doriane Rey

Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), recently announced that it has successfully completed a Phase 1 study evaluating single and multiple ascending doses of ZT-01.

Learn more
Doriane Rey
Previous

New Partnership Between Aridhia and Replica Analytics Powers Rapid, Secure and Compliant Use of Health Data
Next

OBIO's Business Development Skills Program Featured in Canadian Healthcare Technology